NEW YORK (GenomeWeb) – Veracyte has entered into a co-promotion agreement with Genzyme for the Afirma Gene Expression Classifier test in Brazil and Singapore, according to the firm's Form 10-K recently filed with the US Securities and Exchange Commission.

Under the terms of the agreement, Veracyte will pay Genzyme 25 percent of cash receipts from the sale of the Afirma GEC test in Brazil and Singapore over a five-year period that began on Jan. 1, 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.